文献速递肝病

胆汁淤积性与脂肪性肝病的新型治疗靶点

Novel therapeutic targets for cholestatic and fatty liver disease.
PubMed 文献 · Gut · 2021-10-06

本文综述胆汁淤积性与非酒精性脂肪性肝病(NAFLD)共享的病理生理机制及新型治疗靶点。核受体(NRs)调控肝脏脂质与葡萄糖代谢、能量消耗、胆汁酸(BA)稳态及炎症纤维化,其失调参与两类肝病进展,是新型治疗的核心。靶向NRs(如FXR、PPARs、THRβ1)及BA信号通路的药物正在开发,联合策略可能最终必要。

要点

  • 胆汁淤积性与NAFLD共享NRs失调等关键病理机制,是新型治疗靶点。
  • FXR、PPARs及THRβ1等NRs配体是当前在研的主要靶向药物。
  • BA信号可通过FGF19类似物、摄取抑制剂及胆汁肝分流衍生物等调控。

核心结论

  • 靶向核受体及胆汁酸信号通路是胆汁淤积性与脂肪性肝病的新型治疗方向,联合策略可能最终必要。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 胆汁淤积性与NAFLD共享NRs失调、胆汁酸稳态异常、炎症和纤维化等病理机制。
  • FXR和PPARs分别由胆汁酸和脂肪酸激活,已开发高亲和力靶向特定或多亚型的治疗配体。
  • 甲状腺激素受体β1的新型肝脏特异性配体补充了当前NR靶向药物谱。
  • 除FXR配体外,BA信号可通过FGF19类似物、肝细胞和肠上皮细胞摄取抑制剂及胆汁肝分流BA衍生物调控。
  • 其他治疗直接靶向炎症和/或纤维化,联合策略可能最终必要。

临床怎么用

  • 关注NRs(FXR、PPARs、THRβ1)及BA信号通路作为胆汁淤积性与脂肪性肝病的潜在治疗靶点。
  • 联合靶向代谢、炎症和纤维化可能为复杂多因素肝病提供治疗思路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic lipid and glucose metabolism, energy expenditure and bile acid (BA) homoeostasis, as well as inflammation, fibrosis and cellular proliferation. Dysregulation of these processes contributes to the pathogenesis and progression of cholestatic as well as fatty liver disease, placing NRs at the forefront of novel therapeutic approaches. This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed. Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and enterocytes, as well as novel BA derivatives undergoing cholehepatic shunting (instead of enterohepatic circulation). Other therapeutic approaches more directly target inflammation and/or fibrosis as critical events of disease progression. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of these complex and multifactorial disorders.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut. 2021. PMID: 34615727. doi:10.1136/gutjnl-2021-324305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。